Mednet Logo
HomeMedical OncologyQuestion

For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?

3
3 Answers
Mednet Member
Mednet Member
Medical Oncology · University of California Los Angeles, Los Angeles
Neoadjuvant Dose Dense MVAC (ddMVAC) has been shown to be safe and effective in MIBC. However, given the different side effect profile compared to cisplatin gemcitabine, especially in terms of bone marrow suppression, cardiotoxicity, and neurotoxicity, the majority of patients are not receiving ddMV...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Comprehensive Cancer Center

I have used gem cis for the majority of my patients; very occasionally, I have used ddMMVAC for the fit patients. The significant side effects profile for ddMVAC dampens my enthusiasm to use it. I would prefer using gem cis durva over ddMVAC, unless there is a contraindication to adding immunotherap...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic

Our academic practice covers a wide mix of patients, frequently with many comorbidities – this makes it challenging to do dose dense regimens, however, this is certainly a regimen we have used in fitter patients.

Register or Sign In to see full answer

For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC? | Mednet